Dr. Quiroz is the Chief Medical Officer for Solid. He provides leadership and clinical vision for the company and is responsible for the clinical programs for patients with Duchenne.
Prior to joining Solid, Dr. Quiroz served as the Head of Neurodevelopment & Psychiatry, Translational Medicine Neurosciences at Hoffmann-La Roche. A medical graduate from the Pontifical Catholic University of Chile and Board Certified Psychiatrist, he completed his medical training as a Research Fellow at the Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, at the National Institutes of Health in Bethesda, Maryland. He also holds a Master of Business Administration dual degree from Columbia University & London Business School.
Dr. Quiroz received the NARSAD Young Investigator Award, the NCDEU New Investigator Award, the Fellows Award for Research Excellence, and the NIH Clinical Center Director’s Award, among other distinctions. He has designed and conducted numerous proof of concept studies, including studies in orphan designated indications, and has successfully filed New Drug Applications with the FDA during his tenure at Johnson & Johnson Pharmaceutical Research and Development and Hoffmann-La Roche. Dr. Quiroz has published over 45 peer reviewed scientific publications and book chapters in the fields of translational neurosciences and drug development.
He also completed studies as a professional violinist at the National Conservatory in the University of Chile.